IN2014CN00614A - - Google Patents

Info

Publication number
IN2014CN00614A
IN2014CN00614A IN614CHN2014A IN2014CN00614A IN 2014CN00614 A IN2014CN00614 A IN 2014CN00614A IN 614CHN2014 A IN614CHN2014 A IN 614CHN2014A IN 2014CN00614 A IN2014CN00614 A IN 2014CN00614A
Authority
IN
India
Prior art keywords
human ngf
antibody
seq
amino acid
acid sequence
Prior art date
Application number
Other languages
English (en)
Inventor
Masazumi Kamohara
Hirotsugu Tanaka
Yukari Koya
Jun Takasaki
Atsuo Yonezawa
Eiji Yoshimi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of IN2014CN00614A publication Critical patent/IN2014CN00614A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN614CHN2014 2011-08-11 2012-08-10 IN2014CN00614A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトngf抗体

Publications (1)

Publication Number Publication Date
IN2014CN00614A true IN2014CN00614A (sl) 2015-04-03

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
IN614CHN2014 IN2014CN00614A (sl) 2011-08-11 2012-08-10

Country Status (28)

Country Link
US (2) US8986952B2 (sl)
EP (1) EP2743348B1 (sl)
JP (1) JP5376095B2 (sl)
KR (1) KR101999867B1 (sl)
CN (1) CN103748222B (sl)
AR (1) AR087506A1 (sl)
AU (1) AU2012293161B2 (sl)
BR (1) BR112014002576B1 (sl)
CA (1) CA2841181C (sl)
CY (1) CY1119914T1 (sl)
DK (1) DK2743348T3 (sl)
EA (1) EA024292B1 (sl)
ES (1) ES2663968T3 (sl)
HR (1) HRP20180155T1 (sl)
HU (1) HUE036079T2 (sl)
IL (1) IL230797A (sl)
IN (1) IN2014CN00614A (sl)
LT (1) LT2743348T (sl)
ME (1) ME02944B (sl)
MX (1) MX351273B (sl)
NO (1) NO2743348T3 (sl)
PL (1) PL2743348T3 (sl)
PT (1) PT2743348T (sl)
RS (1) RS56876B1 (sl)
SI (1) SI2743348T1 (sl)
TW (1) TWI554519B (sl)
WO (1) WO2013022083A1 (sl)
ZA (1) ZA201400741B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
CA2821515A1 (en) 2010-12-01 2012-06-07 Alder Biopharmaceuticals, Inc. Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトngf抗体
MX2017014911A (es) * 2015-05-22 2018-03-23 Astellas Pharma Inc Fragmento fab de anticuerpo ngf anti-humano novedoso.
CN108883177A (zh) * 2016-03-25 2018-11-23 安斯泰来制药株式会社 含有PEG化抗人NGF抗体Fab’片段的药物组合物
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技(上海)有限公司 抗人ngf抗体及其制备方法和用途
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3855071B2 (ja) * 1993-03-11 2006-12-06 財団法人化学及血清療法研究所 抗hivモノクローナル抗体
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2448956C (en) 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
EP2364728A1 (en) 2003-07-15 2011-09-14 Amgen, Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US9315571B2 (en) 2005-01-24 2016-04-19 Elan Pharma International Limited Specific binding members for NGF
ME00977B (me) * 2007-08-10 2012-06-20 Regeneron Pharma Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
UY32608A (es) 2009-05-04 2010-12-31 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada

Also Published As

Publication number Publication date
PT2743348T (pt) 2018-02-23
ES2663968T3 (es) 2018-04-17
EP2743348A1 (en) 2014-06-18
JP5376095B2 (ja) 2013-12-25
NO2743348T3 (sl) 2018-06-09
KR101999867B1 (ko) 2019-07-12
EA024292B1 (ru) 2016-09-30
US8986952B2 (en) 2015-03-24
ZA201400741B (en) 2014-11-26
CA2841181A1 (en) 2013-02-14
WO2013022083A1 (ja) 2013-02-14
PL2743348T3 (pl) 2018-04-30
CN103748222A (zh) 2014-04-23
JPWO2013022083A1 (ja) 2015-03-05
HUE036079T2 (hu) 2018-06-28
IL230797A (en) 2017-06-29
MX351273B (es) 2017-10-06
BR112014002576B1 (pt) 2022-08-23
HRP20180155T1 (hr) 2018-03-23
EA201490433A1 (ru) 2014-05-30
IL230797A0 (en) 2014-03-31
TWI554519B (zh) 2016-10-21
US20150218265A1 (en) 2015-08-06
SI2743348T1 (sl) 2018-04-30
RS56876B1 (sr) 2018-04-30
AU2012293161A1 (en) 2014-02-06
DK2743348T3 (en) 2018-02-26
TW201319086A (zh) 2013-05-16
LT2743348T (lt) 2018-05-10
CN103748222B (zh) 2015-07-22
MX2014001627A (es) 2014-05-28
EP2743348A4 (en) 2015-04-29
BR112014002576A2 (pt) 2021-01-12
CA2841181C (en) 2022-01-25
ME02944B (me) 2018-04-20
AU2012293161B2 (en) 2017-04-27
CY1119914T1 (el) 2018-06-27
US20140155582A1 (en) 2014-06-05
AR087506A1 (es) 2014-03-26
EP2743348B1 (en) 2018-01-10
KR20140047116A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
IN2014CN00614A (sl)
NZ706377A (en) Il-6 antagonists and uses thereof
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
NZ703653A (en) Anti-fap antibodies and methods of use
NZ611468A (en) Humanized antibodies to liv-1 and use of same to treat cancer
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
NI201200171A (es) Anticuerpos hacia gdf8 humano
NZ610734A (en) Human antibodies to the glucagon receptor
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
NZ594682A (en) Fully human antibodies specific to cadm1
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
NZ701444A (en) Antibodies to matrix metalloproteinase 9
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MY177098A (en) Novel anti-human tslp receptor antibody
NZ714516A (en) Human antibodies to clostridium difficile toxins
MY185811A (en) Novel anti-human tie-2 antibody
MX2012000316A (es) Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos.
NZ595792A (en) Antibodies specific to cadherin-17
JOP20190103A1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
AU2012315616A8 (en) Identification of antigen-specific adaptive immune responses using Arm-PCR and high-throughput sequencing
MX347955B (es) Novedoso anticuerpo anti-receptor de il-23 humano.
EA201491240A1 (ru) Новое антитело против ctgf человека
NZ594452A (en) Anti-mst1r antibodies and uses thereof
MX2018011039A (es) Podocalixina y anticuerpos relacionados con tra, metodos de preparacion y usos como agente terapeutico anticancerigeno.